Syndax Pharmaceuticals, Inc. (SNDX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNDX trades at $20.23 with a market cap of $1.72B and a P/E ratio of -6.10. SNDX moved +4.08% today. Year to date, SNDX is -0.45%; over the trailing twelve months it is +90.44%. Its 52-week range spans $8.58 to $25.59. Analyst consensus is strong buy with an average price target of $39.91. Rallies surfaces SNDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SNDX news today?
Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026: Syndax Pharmaceuticals had 12 Revuforj (revumenib) abstracts accepted for presentation at the European Hematology Association 2026 Congress, covering real-world, frontline, post-transplant maintenance, and relapsed/refractory AML data across KMT2Ar, NPM1m, and NUP98r subtypes. Abstracts include updated Phase 1 and combination trial results and maintenance outcomes.
Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026: Syndax Pharmaceuticals had 12 Revuforj (revumenib) abstracts accepted for presentation at the European Hematology Association 2026 Congress, covering real-world, frontline, post-transplant maintenance, and relapsed/refractory AML data across KMT2Ar, NPM1m, and NUP98r subtypes. Abstracts include updated Phase 1 and combination trial results and maintenance outcomes.
Does Rallies summarize SNDX news?
Yes. Rallies summarizes SNDX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SNDX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.
